Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01122407 · ClinicalTrials.gov registry record · Phase 1

Pathophysiology of Cardiometabolic Risk Factors in African Americans

A Phase 1 study of Obesity and Hypertension, sponsored by Vanderbilt University Medical Center.

Completed
Registry status
Phase 1
Development phase
34
Enrollment target
1
Study location

NCT01122407: Completed Phase 1 study of Obesity and Hypertension, sponsored by Vanderbilt University Medical Center.

NCT01122407 is a Phase 1 study of Obesity and Hypertension that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 34 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01122407, a Phase 1 study of Obesity and Hypertension, has completed, sponsored by Vanderbilt University Medical Center.

COMPLETED
Registry status
Phase 1
Development phase
34 participants
Enrollment target
1
Study location

Study Summary

The overall goal of this proposal is to determine the autonomic and nitric oxide contribution in the pathogenesis of hypertension and insulin resistance in obese African American women. For this purpose we will use two non-FDA approved drugs: Trimethaphan IND# 63826 Approval date 12/20/2001 L-NMMA IND# 41735 Approval date 09/1993

Primary Outcome

Will infuse trimethaphan for until complete autonomic blockade is achieved.

Conditions Studied

Interventions

  • DRUG L-NMMA
  • DRUG Trimethaphan

Study Locations (1)

Tennessee

  • Vanderbilt University Medical Center - Nashville

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2010-01
Est. Completion 2016-11
Phase Phase 1

What the finished NCT01122407 record still lists

NCT01122407 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (96% lower).

The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which L-NMMA is the first listed.

NCT01122407 reports a single indexed study location in Tennessee.

Frequently Asked Questions

What is clinical trial NCT01122407 about?

NCT01122407 is a clinical study titled "Pathophysiology of Cardiometabolic Risk Factors in African Americans". The overall goal of this proposal is to determine the autonomic and nitric oxide contribution in the pathogenesis of hypertension and insulin resistance in obese African American women. For this purpose we will use two non-FDA approved drugs: Trimethaphan IND# 63826 Approval date 12/20/2001 L-NMMA ...

What is the current status of trial NCT01122407?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2010-01. Estimated completion is 2016-11.

What conditions does trial NCT01122407 study?

This clinical trial studies the following conditions: Obesity, Hypertension.

What interventions are being tested in trial NCT01122407?

The interventions under investigation include: L-NMMA (DRUG), Trimethaphan (DRUG).

Who is sponsoring clinical trial NCT01122407?

This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01122407 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01122407's enrollment target sits among peer trials

34 829th of 1053 higher than 221 of 1,053 other Obesity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02897063 · 34 participants · Phase 1

    Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

  • NCT03906617 · 34 participants · Phase 4

    Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine

  • NCT03992378 · 34 participants · NA

    Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis

  • NCT04047849 · 34 participants · Phase 4

    Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01122407, the US trial registry maintained by the National Library of Medicine. NCT01122407 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.